Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Ferris, DG, Samakoses, R, Block, SL, Lazcano-Ponce, E, Restrepo, JA, Mehlsen, J, Chatterjee, A, Iversen, O-E, Joshi, A, Chu, J-L, Krick, AL, Saah, A & Das, R 2017, '4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years', Pediatrics, bind 140, nr. 6. https://doi.org/10.1542/peds.2016-3947

APA

Ferris, D. G., Samakoses, R., Block, S. L., Lazcano-Ponce, E., Restrepo, J. A., Mehlsen, J., Chatterjee, A., Iversen, O-E., Joshi, A., Chu, J-L., Krick, A. L., Saah, A., & Das, R. (2017). 4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years. Pediatrics, 140(6). https://doi.org/10.1542/peds.2016-3947

CBE

Ferris DG, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Mehlsen J, Chatterjee A, Iversen O-E, Joshi A, Chu J-L, Krick AL, Saah A, Das R. 2017. 4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years. Pediatrics. 140(6). https://doi.org/10.1542/peds.2016-3947

MLA

Vancouver

Author

Ferris, Daron G ; Samakoses, Rudiwilai ; Block, Stanley L ; Lazcano-Ponce, Eduardo ; Restrepo, Jaime Alberto ; Mehlsen, Jesper ; Chatterjee, Archana ; Iversen, Ole-Erik ; Joshi, Amita ; Chu, Jian-Li ; Krick, Andrea Likos ; Saah, Alfred ; Das, Rituparna. / 4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years. I: Pediatrics. 2017 ; Bind 140, Nr. 6.

Bibtex

@article{0f22e035d5d54c88874682622057b443,
title = "4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years",
abstract = "OBJECTIVES: We describe the final 10-year data for the long-term follow-up study of the 4-valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents.METHODS: In the base study (V501-018), 1661 sexually inactive boys and girls received the 4vHPV vaccine (early vaccination group [EVG], managed for 9.9 years) or a placebo at day 1, month 2, and month 6. Thereafter, at month 30, the placebo group (catch-up vaccination group [CVG], managed for 7.4 years) received the 4vHPV vaccine by using the same dosing schedule. Long-term anti-HPV type 6, 11, 16, and 18 immune responses were assessed. Effectiveness was estimated by calculating the incidence rate of the primary endpoints (HPV types 6, 11, 16, and 18-related disease or persistent infection).RESULTS: For HPV types 6, 11, and 16, 89% to 96% of subjects remained seropositive through 10-years postvaccination. The preadolescents had 38% to 65% higher geometric mean titers at month 7, which remained 16% to 42% higher at 10 years compared with adolescents. No cases of HPV type 6, 11, 16, and 18-related diseases were observed. Ten subjects had a persistent infection of ≥6 months duration with vaccine-type HPV and 2 subjects had persistent infection for ≥12 months. No new serious adverse events were reported through 10 years.CONCLUSIONS: A 3-dose regimen of the 4vHPV vaccine was immunogenic, clinically effective, and generally well tolerated in preadolescents and adolescents during 10 years of follow-up. These long-term findings support efforts to vaccinate this population against HPV before exposure.",
keywords = "Adolescent, Child, Female, Follow-Up Studies, Humans, Male, Papillomaviridae, Papillomavirus Infections, Papillomavirus Vaccines, Journal Article",
author = "Ferris, {Daron G} and Rudiwilai Samakoses and Block, {Stanley L} and Eduardo Lazcano-Ponce and Restrepo, {Jaime Alberto} and Jesper Mehlsen and Archana Chatterjee and Ole-Erik Iversen and Amita Joshi and Jian-Li Chu and Krick, {Andrea Likos} and Alfred Saah and Rituparna Das",
note = "Copyright {\textcopyright} 2017 by the American Academy of Pediatrics.",
year = "2017",
month = dec,
doi = "10.1542/peds.2016-3947",
language = "English",
volume = "140",
journal = "Pediatrics (English Edition)",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "6",

}

RIS

TY - JOUR

T1 - 4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years

AU - Ferris, Daron G

AU - Samakoses, Rudiwilai

AU - Block, Stanley L

AU - Lazcano-Ponce, Eduardo

AU - Restrepo, Jaime Alberto

AU - Mehlsen, Jesper

AU - Chatterjee, Archana

AU - Iversen, Ole-Erik

AU - Joshi, Amita

AU - Chu, Jian-Li

AU - Krick, Andrea Likos

AU - Saah, Alfred

AU - Das, Rituparna

N1 - Copyright © 2017 by the American Academy of Pediatrics.

PY - 2017/12

Y1 - 2017/12

N2 - OBJECTIVES: We describe the final 10-year data for the long-term follow-up study of the 4-valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents.METHODS: In the base study (V501-018), 1661 sexually inactive boys and girls received the 4vHPV vaccine (early vaccination group [EVG], managed for 9.9 years) or a placebo at day 1, month 2, and month 6. Thereafter, at month 30, the placebo group (catch-up vaccination group [CVG], managed for 7.4 years) received the 4vHPV vaccine by using the same dosing schedule. Long-term anti-HPV type 6, 11, 16, and 18 immune responses were assessed. Effectiveness was estimated by calculating the incidence rate of the primary endpoints (HPV types 6, 11, 16, and 18-related disease or persistent infection).RESULTS: For HPV types 6, 11, and 16, 89% to 96% of subjects remained seropositive through 10-years postvaccination. The preadolescents had 38% to 65% higher geometric mean titers at month 7, which remained 16% to 42% higher at 10 years compared with adolescents. No cases of HPV type 6, 11, 16, and 18-related diseases were observed. Ten subjects had a persistent infection of ≥6 months duration with vaccine-type HPV and 2 subjects had persistent infection for ≥12 months. No new serious adverse events were reported through 10 years.CONCLUSIONS: A 3-dose regimen of the 4vHPV vaccine was immunogenic, clinically effective, and generally well tolerated in preadolescents and adolescents during 10 years of follow-up. These long-term findings support efforts to vaccinate this population against HPV before exposure.

AB - OBJECTIVES: We describe the final 10-year data for the long-term follow-up study of the 4-valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents.METHODS: In the base study (V501-018), 1661 sexually inactive boys and girls received the 4vHPV vaccine (early vaccination group [EVG], managed for 9.9 years) or a placebo at day 1, month 2, and month 6. Thereafter, at month 30, the placebo group (catch-up vaccination group [CVG], managed for 7.4 years) received the 4vHPV vaccine by using the same dosing schedule. Long-term anti-HPV type 6, 11, 16, and 18 immune responses were assessed. Effectiveness was estimated by calculating the incidence rate of the primary endpoints (HPV types 6, 11, 16, and 18-related disease or persistent infection).RESULTS: For HPV types 6, 11, and 16, 89% to 96% of subjects remained seropositive through 10-years postvaccination. The preadolescents had 38% to 65% higher geometric mean titers at month 7, which remained 16% to 42% higher at 10 years compared with adolescents. No cases of HPV type 6, 11, 16, and 18-related diseases were observed. Ten subjects had a persistent infection of ≥6 months duration with vaccine-type HPV and 2 subjects had persistent infection for ≥12 months. No new serious adverse events were reported through 10 years.CONCLUSIONS: A 3-dose regimen of the 4vHPV vaccine was immunogenic, clinically effective, and generally well tolerated in preadolescents and adolescents during 10 years of follow-up. These long-term findings support efforts to vaccinate this population against HPV before exposure.

KW - Adolescent

KW - Child

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Male

KW - Papillomaviridae

KW - Papillomavirus Infections

KW - Papillomavirus Vaccines

KW - Journal Article

U2 - 10.1542/peds.2016-3947

DO - 10.1542/peds.2016-3947

M3 - Journal article

C2 - 29167376

VL - 140

JO - Pediatrics (English Edition)

JF - Pediatrics (English Edition)

SN - 0031-4005

IS - 6

ER -

ID: 52225214